+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

South & Central America Genotyping Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product and Services, Technology, Application, and End User

  • PDF Icon

    Report

  • 152 Pages
  • September 2022
  • The Insight Partners
  • ID: 5668438
UP TO OFF until Mar 31st 2024
The genotyping market in South & Central America is expected to grow from US$ 772.17 million in 2022 to US$ 1,889.89 million by 2028. It is estimated to grow at a CAGR of 16.1% from 2022 to 2028.

According to the study, personalized medicine is the customization of medical treatment to each patient's unique traits. The method is based on scientific advances in understanding how a person's unique molecular and genetic profile influences susceptibility to diseases and predicts which medical treatments are safe and effective and which are not. Senior government officials, corporate leaders, healthcare practitioners, and the general public have embraced genomics and personalized medicine over the last decade. Genomic medicine is a fundamental component of personalized medicine, a fast-growing health care branch guided by each person's unique clinical, genetic, genomic, and environmental information.

The fundamentals of genomic and personalized medicine will require the development, standardization, and integration of several essential tools into health systems and clinical workflows as medicine embraces genomic tools that enable more precise disease prediction and treatment, such as "whole-genome" interrogation of sequence variation, transcription, proteins, and metabolites. Among the techniques available are health risk assessment, family health history, and clinical decision assistance for complex risk and predictive information.

When combined with genomic data, these tools will enable a paradigm change toward a holistic strategy that will detect individual risks and guide clinical treatment and decision-making, laying the groundwork for a more informed and effective patient care approach. Genome-guided therapy, dose selection, DNA-based risk assessment for common complex diseases, and molecular signatures for cancer diagnosis and prognosis are examples of how genome information has already enabled personalized healthcare. For instance, genome-guided treatment is perhaps the most well-studied effect of precision medicine on health care today.

Clinicians have used genotype data as a guideline to calculate the correct warfarin dose. To assist doctors in optimizing pharmacological therapy based on genetic test results, the Clinical Pharmacogenetics Implementation Consortium produced genotype-based drug guidelines. For individuals with breast or lung cancer, genomic analysis of tumors can help guide tailored therapeutic approaches. When precision medicine is integrated into healthcare, it can provide more accurate diagnoses, anticipate disease risk before symptoms appear, and provide individualized treatment plans that maximize safety and efficiency.

Furthermore, data from individual genomes, a rapidly developing technology area, is causing a social and information revolution among customers, undoubtedly influencing healthcare decision-making. Although these and other scientific discoveries are making their way from the lab to the clinic, widespread acceptance of genomic and personalized medicine will necessitate significant changes in regulatory and reimbursement procedures and legislative privacy laws. Thus, customized healthcare challenges will be met and overcome with the assurance that the research behind genetic medicine is decent and that the practice of medicine that it informs is evidence-based. Over time, there has been a steady trend away from the old 'one pill fits all' strategy and toward a more individualized, patient-centered approach. Patients, health, and diseases are now treated with a more predictive, preventive, participatory, and individualized approach in medicine. This so-called P4 medicine has numerous problems and roadblocks, but it also presents numerous opportunities for improving care and therapeutic outcomes; therefore, such developments will represent a demand for personalized medicine, offering a growth curve for the market over the study period.

South & Central America Genotyping Market Segmentation

The South & Central America genotyping market is segmented by products and services, technology, application, end user, and country.
  • Based on products and services, the market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment is dominating the market in 2022.
  • Based on technology, the market is segmented into microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption/ionization-time of flight (Maldi-ToF) mass spectrometry, polymerase chain reaction (PCR), and others. The PCR segment is dominating the market in 2022.
  • Based on application, the market is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and others. The diagnostics and personalized medicine segment is dominating the market in 2022.
  • Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and others. The diagnostics and research laboratories segment is dominating the market in 2022.
  • Based on country, the market is segmented into Brazil, Argentina, and the rest of South & Central America. Further, Brazil is dominating the market in 2022.
A few key players dominating the South & Central America genotyping market are BioTek Instruments, Inc.; F. Hoffmann-La Roche Ltd.; Illumina, Inc.; Integrated DNA Technologies, Inc.; MERCK KGaA; QIAGEN; and Thermo Fisher Scientific Inc.
Frequently Asked Questions about the South & Central American Genotyping Market

What is the estimated value of the South & Central American Genotyping Market?

The South & Central American Genotyping Market was estimated to be valued at $772.17 Million in 2022.

What is the growth rate of the South & Central American Genotyping Market?

The growth rate of the South & Central American Genotyping Market is 16.1%, with an estimated value of $1889.89 Million by 2028.

What is the forecasted size of the South & Central American Genotyping Market?

The South & Central American Genotyping Market is estimated to be worth $1889.89 Million by 2028.

Who are the key companies in the South & Central American Genotyping Market?

Key companies in the South & Central American Genotyping Market include BioTek Instruments, Inc., F. Hoffmann, La Roche Ltd., Illumina, Inc., Integrated DNA Technologies, Inc., MERCK KGaA, QIAGEN and Thermo Fisher Scientific Inc.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 South & Central America Genotyping Market - By Product and Services
1.3.2 South & Central America Genotyping Market - By Technology
1.3.3 South & Central America Genotyping Market - By Application
1.3.4 South & Central America Genotyping Market - By End User
1.3.5 South & Central America Genotyping Market - By Country
2. South & Central America Genotyping Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Genotyping Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 South & Central America PEST Analysis
4.3 Experts Opinion
5. South & Central America Genotyping Market- Key Market Dynamics
5.1 Market Drivers
5.1.1 Use of Genotyping in Drug Development for Genetic and Rare Diseases
5.1.2 Technological Advancements and Rising R&D Investments in Pharmaceutical and Biotechnology
5.2 Market Restraints
5.2.1 High Cost of Equipment and Shortage of skilled Professionals required for Genotyping process
5.3 Market Opportunities
5.3.1 Wide Applications of Genotyping
5.4 Future Trends
5.4.1 Rising focus on Personalized Medicine
5.5 Impact analysis
6. Genotyping Market- South & Central America Analysis
6.1 South & Central America Genotyping Market Revenue Forecast and Analysis
7. South & Central America Genotyping Market- by Product and Services
7.1 Overview
7.2 South & Central America Genotyping Market, By Product and Services, 2022 & 2028 (%)
7.3 Reagents and Kits
7.3.1 Overview
7.3.2 Reagents and Kits: South & Central America Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
7.4 Genotyping Services
7.4.1 Overview
7.4.2 Genotyping Services: South & Central America Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
7.5 Bioinformatics
7.5.1 Overview
7.5.2 Bioinformatics: South & Central America Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
7.6 Instruments
7.6.1 Overview
7.6.2 Instruments: South & Central America Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
8. South & Central America Genotyping Market- by Technology
8.1 Overview
8.2 South & Central America Genotyping Market Share by Technology - 2022 & 2028 (%)
8.3 Polymerase Chain Reaction (PCR)
8.3.1 Overview
8.3.2 Polymerase Chain Reaction: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
8.4 Capillary Electrophoresis (CE)
8.4.1 Overview
8.4.2 Capillary Electrophoresis: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
8.5 Sequencing
8.5.1 Overview
8.5.2 Sequencing: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
8.6 Microarrays
8.6.1 Overview
8.6.2 Microarrays: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
8.7 Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry
8.7.1 Overview
8.7.2 Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
9. South & Central America Genotyping Market-by Application
9.1 Overview
9.2 South & Central America Genotyping Market Share by Application - 2022 & 2028 (%)
9.3 Diagnostics and Personalized Medicine
9.3.1 Overview
9.3.2 Diagnostics and Personalized Medicine: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
9.4 Pharmacogenomics
9.4.1 Overview
9.4.2 Pharmacogenomics: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
9.5 Animal Genetics
9.5.1 Overview
9.5.2 Animal Genetics: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
9.6 Agricultural Biotechnology
9.6.1 Overview
9.6.2 Agricultural Biotechnology: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
10. South & Central America Genotyping Market- by End User
10.1 Overview
10.2 South & Central America Genotyping Market Share by End User- 2022 & 2028 (%)
10.3 Diagnostic and Research Laboratories
10.3.1 Overview
10.3.2 Diagnostic and Research Laboratories: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
10.4 Pharmaceutical and Biopharmaceutical Companies
10.4.1 Overview
10.4.2 Pharmaceutical and Biopharmaceutical Companies: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
10.5 Academic Institutes
10.5.1 Overview
10.5.2 Academic Institutes: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
10.6 Others
10.6.1 Overview
10.6.2 Others: South & Central America Genotyping Market Revenue and Forecast to 2028 (US$ Million)
11. South & Central America Genotyping Market- Country Analysis
11.1 South & Central America Genotyping Market Revenue and Forecasts to 2028
11.1.1 Overview
11.1.3 South & Central America Genotyping Market Revenue and Forecasts to 2028, By Country (%)
11.1.3.1 Argentina Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
11.1.3.1.1 Overview
11.1.3.1.2 Argentina Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
11.1.3.1.3 Argentina: Genotyping Market Revenue and Forecasts to 2028, By Product and Services (US$ Million)
11.1.3.1.4 Argentina: Genotyping Market Revenue and Forecasts to 2028, By Technology (US$ Million)
11.1.3.1.5 Argentina: Genotyping Market Revenue and Forecasts to 2028, By Application (US$ Million)
11.1.3.1.6 Argentina: Genotyping Market Revenue and Forecasts to 2028, By End User (US$ Million)
11.1.3.2 Brazil: Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
11.1.3.2.1 Overview
11.1.3.2.2 Brazil: Genotyping Market Revenue and Forecasts to 2028 (US$ Million)
11.1.3.2.3 Brazil: Genotyping Market Revenue and Forecasts to 2028, By Product and Services (US$ Million)
11.1.3.2.4 Brazil: Genotyping Market Revenue and Forecasts to 2028, By Technology (US$ Million)
11.1.3.2.5 Brazil: Genotyping Market Revenue and Forecasts to 2028, By Application (US$ Million)
11.1.3.2.6 Brazil: Genotyping Market Revenue and Forecasts to 2028, By End User (US$ Million)
11.1.3.3 Rest of South & Central America: Genotyping Market- Revenue and Forecast to 2028 (USD Mn)
11.1.3.3.1 Overview
11.1.3.3.2 Rest of South & Central America: Genotyping Market- Revenue and Forecast to 2028 (USD Mn)
11.1.3.3.3 Rest of South & Central America: Genotyping Market Revenue and Forecasts to 2028, By Product and Services (US$ Million)
11.1.3.3.4 Rest of South & Central America: Genotyping Market Revenue and Forecasts to 2028, By Technology (US$ Million)
11.1.3.3.5 Rest of South & Central America: Genotyping Market Revenue and Forecasts to 2028, By Application (US$ Million)
11.1.3.3.6 Rest of South & Central America: Genotyping Market Revenue and Forecasts to 2028, By End User (US$ Million)
12. South & Central America Genotyping Market Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 F. HOFFMANN-LA ROCHE LTD.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 INTEGRATED DNA TECHNOLOGIES, INC. (DANAHER)
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 QIAGEN
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 MERCK KGaA
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 THERMO FISHER SCIENTIFIC INC.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 BioTek Instruments, Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Illumina, Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms

Companies Mentioned

A selection of companies mentioned in this report includes:

  • BioTek Instruments, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • MERCK KGaA
  • QIAGEN
  • Thermo Fisher Scientific Inc